$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514399257 Filed on November 06, 2014

Income Statement

Concept	2014 Q3	2013 Q3
Revenue	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.300M	$2.190M
YoY Change	5.02%	-4.78%
% of Gross Profit
Research & Development	$1.358M	$1.297M
YoY Change	4.74%	14.76%
% of Gross Profit
Depreciation & Amortization	$170.0K	$160.0K
YoY Change	6.25%	0.0%
% of Gross Profit
Operating Expenses	$3.826M	$1.297M
YoY Change	195.07%	14.76%
Operating Profit	-$3.826M	-$3.650M
YoY Change	4.81%	1.56%
Interest Expense	$80.00K	-$900.0K
YoY Change	-108.89%	-172.0%
% of Operating Profit
Other Income/Expense, Net	$77.00K	-$903.0K
YoY Change	-108.53%	-172.41%
Pretax Income	-$3.750M	-$4.550M
YoY Change	-17.58%	93.62%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.749M	-$4.553M
YoY Change	-17.66%	93.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$20.94K	-$34.58K
COMMON SHARES
Basic Shares Outstanding	180.3M shares	140.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.77M	$8.250M
YoY Change	115.39%	348.37%
Cash & Equivalents	$17.77M	$8.254M
Short-Term Investments
Other Short-Term Assets		$50.00K
YoY Change		150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$17.77M	$8.299M
YoY Change	114.17%	346.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.56K	$31.83K
YoY Change	200.21%	6.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$27.00K	$27.00K
YoY Change	0.0%	-10.0%
Total Long-Term Assets	$3.874M	$4.481M
YoY Change	-13.55%	-12.98%
TOTAL ASSETS
Total Short-Term Assets	$17.77M	$8.299M
Total Long-Term Assets	$3.874M	$4.481M
Total Assets	$21.65M	$12.78M
YoY Change	69.38%	82.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$480.0K	$200.0K
YoY Change	140.0%	-28.57%
Accrued Expenses	$400.0K	$340.0K
YoY Change	17.65%	-79.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$881.1K	$542.5K
YoY Change	62.42%	-72.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.230M	$3.510M
YoY Change	-64.96%	115.34%
Total Long-Term Liabilities	$1.230M	$3.510M
YoY Change	-64.96%	115.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$881.1K	$542.5K
Total Long-Term Liabilities	$1.230M	$3.510M
Total Liabilities	$2.108M	$4.057M
YoY Change	-48.03%	13.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.1M	-$129.5M
YoY Change	21.36%
Common Stock	$180.3K	$140.0K
YoY Change	28.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.54M	$8.723M
YoY Change
Total Liabilities & Shareholders Equity	$21.65M	$12.78M
YoY Change	69.38%	82.32%

Cashflow Statement

Concept	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$3.749M	-$4.553M
YoY Change	-17.66%	93.99%
Depreciation, Depletion And Amortization	$170.0K	$160.0K
YoY Change	6.25%	0.0%
Cash From Operating Activities	-$3.400M	-$2.760M
YoY Change	23.19%	23.77%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$10.00K
YoY Change	600.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$70.00K	-$10.00K
YoY Change	600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.120M	6.390M
YoY Change	-51.17%
NET CHANGE
Cash From Operating Activities	-3.400M	-2.760M
Cash From Investing Activities	-70.00K	-10.00K
Cash From Financing Activities	3.120M	6.390M
Net Change In Cash	-350.0K	3.620M
YoY Change	-109.67%	-262.33%
FREE CASH FLOW
Cash From Operating Activities	-$3.400M	-$2.760M
Capital Expenditures	-$70.00K	-$10.00K
Free Cash Flow	-$3.330M	-$2.750M
YoY Change	21.09%	23.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	33334	shares
CY2013Q2	us-gaap	Litigation Reserve LitigationReserve	100000
CY2014Q2	us-gaap	Loss Contingency Receivable LossContingencyReceivable	2240000
CY2014Q2	pvct	Reimbursement Receivable Percentage ReimbursementReceivablePercentage	0.25	pure
CY2013Q2	pvct	Common Stock Unit Beneficial Conversion Amount CommonStockUnitBeneficialConversionAmount	1025950
CY2013Q2	pvct	Common Stock Unit Fair Value Of Warrants Recorded On Issuance CommonStockUnitFairValueOfWarrantsRecordedOnIssuance	1297950
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8253591
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3036218	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2014Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	372000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	180299739	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180299739	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.25
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	180299739	shares
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	434479
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	881061
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	180300
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157110050
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	19539425
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	311579
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21647723
CY2014Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7963957
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176469175
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	91282
CY2014Q3	us-gaap	Liabilities Liabilities	2108298
CY2014Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	478200
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17773680
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95555
CY2014Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3751488
CY2014Q3	us-gaap	Assets Assets	21647723
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	17773680
CY2014Q3	pvct	Number Of Non Employee To Whom Consulting Services Paid NumberOfNonEmployeeToWhomConsultingServicesPaid	1	Directors
CY2014Q3	pvct	Warrant Liability WarrantLiability	1227237
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1221701
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	159751724	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	159751724	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	429331
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	33
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	512946
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	159752
CY2014Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	1120000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146050820
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	6628666
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102795
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20008184
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7460617
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	152519701
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	61282
CY2013Q4	us-gaap	Liabilities Liabilities	13379518
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	348869
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15696243
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30113
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4254828
CY2013Q4	us-gaap	Assets Assets	20008184
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	15696243
CY2013Q4	pvct	Warrant Liability WarrantLiability	12866572
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	300000	shares
CY2014Q2	pvct	Future Payments Ratio Of Contingent Consideration FuturePaymentsRatioOfContingentConsideration	2	pure
CY2014Q2	pvct	Annual Cash Bonus Percentage AnnualCashBonusPercentage	0.70	pure
CY2014Q3	pvct	Attorneys Fees Awarded By Court In Legal Settlement AttorneysFeesAwardedByCourtInLegalSettlement	911000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	150000	shares
CY2014Q1	pvct	Convertible Preferred Stock Shares To Be Converted To Common Stock Shares ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares	0	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7707571
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	126503388	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10183724
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6650
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12288898
	us-gaap	Net Income Loss NetIncomeLoss	-11100250
	us-gaap	Investment Income Interest InvestmentIncomeInterest	576
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	45284
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	142310
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2815519
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	503340
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7031890
	us-gaap	Depreciation Depreciation	4650
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14746111
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	142310
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	72014
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6650
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1188648
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	150000	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6864865
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-40971
	pvct	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	1527518
	pvct	Net Proceeds From Sales Of Preferred Stock And Warrants NetProceedsFromSalesOfPreferredStockAndWarrants	2550000
	pvct	Gain Loss On Fair Value Of Warrant Liability GainLossOnFairValueOfWarrantLiability	-917102
	pvct	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	-917102
	pvct	Net Proceeds From Sales Of Common Stock And Warrants NetProceedsFromSalesOfCommonStockAndWarrants	12204174
	pvct	Cash Paid For Preferred Dividend CashPaidForPreferredDividend	29063
	pvct	Proceeds From Exercises Of Warrants And Stock Options ProceedsFromExercisesOfWarrantsAndStockOptions	21000
	pvct	Issuance Of Stock For Services IssuanceOfStockForServices	312000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
	dei	Trading Symbol TradingSymbol	PVCT
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.77
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> 2. <b>Nature of Operations</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates, or sell or license the Company’s OTC products or non-core technologies.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9669940
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	150000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	173729010	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.77
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	0
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12367172
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70590
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11059230
	us-gaap	Net Income Loss NetIncomeLoss	-11059230
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4226
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115645
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	85000
CY2014Q1	pvct	Aggregate Exercise Price Of Warrants Exercised AggregateExercisePriceOfWarrantsExercised	2672364
CY2014Q1	pvct	Number Of Warrants Exercised During Period NumberOfWarrantsExercisedDuringPeriod	3036218	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3541520
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	503340
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2077437
	us-gaap	Depreciation Depreciation	5148
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11817967
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	115645
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	238784
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-70590
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8322312
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	129331
	pvct	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	1354508
	pvct	Gain Loss On Fair Value Of Warrant Liability GainLossOnFairValueOfWarrantLiability	1303716
	pvct	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	1303716
	pvct	Litigation Settlement Repayment Period LitigationSettlementRepaymentPeriod	P5Y
	pvct	Adjustments To Additional Paid In Capital Employee Compensation From Stock Options Value AdjustmentsToAdditionalPaidInCapitalEmployeeCompensationFromStockOptionsValue	115645
	pvct	Stock Issued During Period Warrants And Stock Options Exercised Value StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue	4347886
	pvct	Payment For Alleged Claims And Plaintiff Legal Fees PaymentForAllegedClaimsAndPlaintiffLegalFees	911000
	pvct	Net Proceeds From Sales Of Common Stock And Warrants NetProceedsFromSalesOfCommonStockAndWarrants	7470081
	pvct	Proceeds From Exercises Of Warrants And Stock Options ProceedsFromExercisesOfWarrantsAndStockOptions	4347886
	pvct	Amount Reclassified From Warrant Liability To Equity AmountReclassifiedFromWarrantLiabilityToEquity	10335619
	pvct	Warrant Issued During Period For Services Value WarrantIssuedDuringPeriodForServicesValue	1354508
	pvct	Issuance Of Stock For Services IssuanceOfStockForServices	346250
	pvct	Stock Issued During Period For Services Value StockIssuedDuringPeriodForServicesValue	346250
	pvct	Issuance Of Common Stock And Warrants Pursuant To Regulation D Value IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue	7470081
CY2014Q1	pvct	Convertible Preferred Stock Shares To Be Converted To Common Stock Shares ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares	33334	shares
CY2014Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	6000
CY2013Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2013Q1	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	859833	shares
CY2013Q1	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	-311062
CY2013Q1	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	1924973	shares
CY2013Q1	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	409640
CY2014Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2014Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08	pure
CY2014Q1	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	121500	shares
CY2014Q1	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	-1153835
CY2014Q1	pvct	Warrants Exercised On Cashless Basis WarrantsExercisedOnCashlessBasis	12522198	shares
CY2014Q1	pvct	Stock Issued During Period Shares Warrants Exercised On Cashless Basis StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis	9100824	shares
CY2014Q1	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	733000	shares
CY2014Q1	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	900317
CY2013Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2013Q2	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	1051500	shares
CY2013Q2	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	221149
CY2013Q2	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	2605000	shares
CY2013Q2	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	931655
CY2014Q2	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	2000000	shares
CY2014Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2014Q2	pvct	Gross Proceeds From Sales Of Common Stock And Warrants GrossProceedsFromSalesOfCommonStockAndWarrants	5000000
CY2014Q2	pvct	Purchase Price Of Common Stock With Warrants PurchasePriceOfCommonStockWithWarrants	2.50
CY2014Q2	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	315000	shares
CY2014Q2	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	186262
CY2014Q2	pvct	Warrants Exercised On Cashless Basis WarrantsExercisedOnCashlessBasis	1594082	shares
CY2014Q2	pvct	Aggregate Exercise Price Of Warrants Exercised AggregateExercisePriceOfWarrantsExercised	372000
CY2014Q2	pvct	Number Of Warrants Exercised During Period NumberOfWarrantsExercisedDuringPeriod	372000	shares
CY2014Q2	pvct	Stock Issued During Period Shares Warrants Exercised On Cashless Basis StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis	915467	shares
CY2014Q2	pvct	Percentage Of Common Shares Issuable On Exercise Of Each Warrant PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant	1.00	pure
CY2014Q2	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	202000	shares
CY2014Q2	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	450002
CY2013Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	131573656	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3650190
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4591385
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-4552695
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	293
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	142310
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1296654
CY2013Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167780
CY2013Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	38690
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2185756
CY2013Q3	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	136500	shares
CY2013Q3	pvct	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	-902798
CY2013Q3	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	-337244
CY2013Q3	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	442000	shares
CY2013Q3	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	186223
CY2014Q3	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	3586300	shares
CY2014Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	75000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	179088989	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3825681
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3748547
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3748547
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1410
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115645
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1358102
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167780
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2299799
CY2014Q3	pvct	Purchase Price Of Common Stock With Warrants PurchasePriceOfCommonStockWithWarrants	1.00
CY2014Q3	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited	228500	shares
CY2014Q3	pvct	Gain Loss On Change In Fair Value Of Warrant Liability GainLossOnChangeInFairValueOfWarrantLiability	75724
CY2014Q3	pvct	Gain Loss On Revaluation Of Warrants Liability GainLossOnRevaluationOfWarrantsLiability	-16734
CY2014Q3	pvct	Percentage Of Common Shares Issuable On Exercise Of Each Warrant PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant	0.50	pure
CY2014Q3	pvct	Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued	6000	shares
CY2014Q3	pvct	Consulting Costs Relates To Warrant Issued ConsultingCostsRelatesToWarrantIssued	4189
CY2014Q3	pvct	Aggregate Amount Of Common Stock AggregateAmountOfCommonStock	3586300

Files In Submission

Name	View Source	Status
0001193125-14-399257-index-headers.html	Edgar Link	pending
0001193125-14-399257-index.html	Edgar Link	pending
0001193125-14-399257.txt	Edgar Link	pending
0001193125-14-399257-xbrl.zip	Edgar Link	pending
d803287d10q.htm	Edgar Link	pending
d803287dex311.htm	Edgar Link	pending
d803287dex312.htm	Edgar Link	pending
d803287dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pvct-20140930.xml	Edgar Link	completed
pvct-20140930.xsd	Edgar Link	pending
pvct-20140930_cal.xml	Edgar Link	unprocessable
pvct-20140930_def.xml	Edgar Link	unprocessable
pvct-20140930_lab.xml	Edgar Link	unprocessable
pvct-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2014 Q3 Form 10-Q Financial Statement

#000119312514399257 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2014 Q3 Form 10-Q Financial Statement

#000119312514399257 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct